Safety of diagnostic coronary angiography during uninterrupted therapeutic warfarin treatment

被引:47
作者
Annala, Anal-Pekka [2 ]
Karjalainen, Pasi P. [2 ]
Porela, Pekka [1 ]
Nyman, Kai [3 ]
Ylitalo, Antti [2 ]
Airaksinen, K. E. Juhani [1 ]
机构
[1] Turku Univ Hosp, Dept Med, FIN-20520 Turku, Finland
[2] Satakunta Cent Hosp, Dept Cardiol, Pori, Finland
[3] Jyvaskyla Cent Hosp, Dept Med, Jyvaskyla, Finland
关键词
D O I
10.1016/j.amjcard.2008.04.003
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Long-term warfarin therapy is assumed to increase bleeding and access site complications after coronary angiography and it is often recommended to postpone invasive procedures to reach international normalized ratio (INR) levels < 1.8. To assess the safety and feasibility of diagnostic coronary angiography during uninterrupted warfarin therapy, we retrospectively analyzed all consecutive patients (n = 258) on warfarin therapy referred for diagnostic coronary angiography in 2 centers with long experience in uninterrupted warfarin therapy during coronary angiography and in 1 center with a policy of preprocedural warfarin pause. An age- and gender-matched control group (n = 258) with similar disease presentation (unstable or stable symptoms) was collected from each center. Radial access was used in 56% of patients in the warfarin group and in 60% of controls (p = 0.21). There was no difference in access site and bleeding complications (1.9% vs 1.6%) or major adverse cardiovascular and cerebrovascular events (0.4% vs 0.8%) between the warfarin group and their controls. Warfarin was interrupted in 80 patients (31%), and bridging therapy was used in 24 of these patients (30%). INR levels were higher in the uninterrupted warfarin group (2.3 vs 1.9, p < 0.001), but the incidence of access site complications was not higher (1.7%) than in patients (n = 80) with a warfarin pause (2.5%) or in patients with pause and bridging therapy (8.3%). Need for blood transfusions (n = 2) occurred only in patients with bridging therapy. Access site complications were more common in the 22 patients with supratherapeutic anticoagulation (INR > 3) than in patients with therapeutic periprocedural INR (9.1% vs 1.5%, p < 0.05). In conclusion, a simple strategy of performing coronary angiography during uninterrupted therapeutic warfarin anticoagulation is a tempting alternative to bridging therapy and is likely to lead to considerable cost savings. (C) 2008 Elsevier Inc. All rights reserved.
引用
收藏
页码:386 / 390
页数:5
相关论文
共 19 条
[1]   The pharmacology and management of the vitamin K antagonists [J].
Ansell, J ;
Hirsh, J ;
Poller, L ;
Bussey, H ;
Jacobson, A ;
Hylek, E .
CHEST, 2004, 126 (03) :204S-233S
[2]   Effectiveness of manual pressure hemostasis following transfemoral coronary angiography in patients on therapeutic warfarin anticoagulation [J].
El-Jack, SS ;
Ruygrok, PN ;
Webster, MWI ;
Stewart, JT ;
Bass, NM ;
Armstrong, GP ;
Ormiston, JA ;
Pornratanarangsi, S .
AMERICAN JOURNAL OF CARDIOLOGY, 2006, 97 (04) :485-488
[3]   Validation of clinical classification schemes for predicting stroke - Results from the national registry of Atrial Fibrillation [J].
Gage, BF ;
Waterman, AD ;
Shannon, W ;
Boechler, M ;
Rich, MW ;
Radford, MJ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (22) :2864-2870
[4]   Risk of thromboembolism with short-term interruption of warfarin therapy [J].
Garcia, David A. ;
Regan, Susan ;
Henault, Lori E. ;
Upadhyay, Ashish ;
Baker, Jaclyn ;
Othman, Mohamed ;
Hylek, Elaine M. .
ARCHIVES OF INTERNAL MEDICINE, 2008, 168 (01) :63-69
[5]  
Grossman W., 2000, GROSSMANS CARDIAC CA, P1
[6]   Drug insight: antithrombotic therapy after percutaneous coronary intervention in patients with an indication for anticoagulation [J].
Helft, Gerard ;
Gilard, Martine ;
Le Feuvre, Claude ;
Zaman, Azfar G. .
NATURE CLINICAL PRACTICE CARDIOVASCULAR MEDICINE, 2006, 3 (12) :673-680
[7]   Coronary angiography in the fully anticoagulated patient: The transradial route is successful and safe [J].
Hildick-Smith, DJR ;
Walsh, JT ;
Lowe, MD ;
Petch, MC .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 58 (01) :8-10
[8]   Oral anticoagulants: Mechanism of action, clinical effectiveness, and optimal therapeutic range [J].
Hirsh, J ;
Dalen, JE ;
Anderson, DR ;
Poller, L ;
Bussey, H ;
Ansell, J ;
Deykin, D .
CHEST, 2001, 119 (01) :8S-21S
[9]   Elective coronary angiography and percutaneous coronary intervention during uninterrupted warfarin therapy [J].
Jessup, DB ;
Coletti, AT ;
Muhlestein, JB ;
Barry, WH ;
Shean, FC ;
Whisenant, BK .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2003, 60 (02) :180-184
[10]   Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting [J].
Karjalainen, Pasi P. ;
Porela, Pekka ;
Ylitalo, Antti ;
Vikman, Saila ;
Nyman, Kai ;
Vaittinen, Mari-Anne ;
Airaksinen, Tuukka J. ;
Niemela, Matti ;
Vahlberg, Tero ;
Airaksinen, K. E. Juhani .
EUROPEAN HEART JOURNAL, 2007, 28 (06) :726-732